Catalio Capital Management, LP
CIK: 1958125
Holdings (47)
Q3 2026 13F, quarter ended Sep 30, 2026, filed Nov 16, 2026
- AVLN
AVALYN PHARMACEUTICALS INC
$48.4M
1.70M sh8.99%+1.4% - BMY
BRISTOL-MYERS SQUIBB CO
$31.18M
499,716 sh5.79%+21.0% - BBIO
BRIDGEBIO PHARMA INC
$27.97M
425,111 sh5.20%-6.6% - PBLS
PARABILIS MEDICINES INC
$26.61M
824,043 sh4.94%+0.0% - JNJ
JOHNSON & JOHNSON
$26.34M
99,496 sh4.89%-28.4% - ASND
ASCENDIS PHARMA A/S
$23.11M
101,445 sh4.29%+219.4% - ARWR
ARROWHEAD PHARMACEUTICALS IN
$20.63M
315,247 sh3.83%New - SNDX
SYNDAX PHARMACEUTICALS INC
$19.24M
1.02M sh3.57%-15.8% - DFTX
DEFINIUM THERAPEUTICS INC
$18.95M
497,964 sh3.52%-11.5% - CELC
CELCUITY INC
$18.34M
230,609 sh3.41%New - SEPN
SEPTERNA INC
$17.77M
454,015 sh3.30%-15.3% - GH
GUARDANT HEALTH INC
$16.51M
92,579 sh3.07%New - PTGX
PROTAGONIST THERAPEUTICS INC
$15.84M
112,418 sh2.94%+5.3% - TXG
10X GENOMICS INC
$14.82M
164,029 sh2.75%New - AMLX
AMYLYX PHARMACEUTICALS INC
$14.72M
505,882 sh2.73%New - MLYS
MINERALYS THERAPEUTICS INC
$14.66M
583,364 sh2.72%-10.1% - EW
EDWARDS LIFESCIENCES CORP
$13.91M
161,121 sh2.58%+29.1% - CRVS
CORVUS PHARMACEUTICALS INC
$11.77M
1.02M sh2.19%-5.5% - MANE
VERADERMICS INC
$11.6M
95,646 sh2.15%+108.6% - ENTX
ENTERA BIO LTD
$11.41M
3.92M sh2.12%New - IRON
DISC MEDICINE INC
$11.31M
172,709 sh2.10%+8.4% - ODTX
ODYSSEY THERAPEUTICS INC
$10.17M
457,839 sh1.89%+0.0% - FDMT
4D MOLECULAR THERAPEUTICS IN
$9.8M
684,753 sh1.82%+45.3% - RARE
ULTRAGENYX PHARMACEUTICAL IN
$9.04M
601,760 sh1.68%+90.3% - BMRN
BIOMARIN PHARMACEUTICAL INC
$8.7M
144,971 sh1.62%New - ANNX
ANNEXON INC
$8.4M
1.99M sh1.56%New - RYTM
RHYTHM PHARMACEUTICALS INC
$8.15M
85,614 sh1.51%New - GPCR
STRUCTURE THERAPEUTICS INC
$8.13M
260,109 sh1.51%-6.0% - NKTR
NEKTAR THERAPEUTICS
$7.68M
126,817 sh1.43%New - IMCR
IMMUNOCORE HLDGS PLC
$6.42M
211,985 sh1.19%+43.2% - COGT
COGENT BIOSCIENCES INC
$5.37M
167,716 sh1.00%New - KLRA
KAILERA THERAPEUTICS INC
$5.35M
468,750 sh0.99%+0.0% - NTRA
NATERA INC
$5.18M
12,530 sh0.96%-84.8% - GUTS
FRACTYL HEALTH INC
$4.81M
8.84M sh0.89%+43.3% - KARD
KARDIGAN INC
$4.61M
312,500 sh0.86%+0.0% - ELDN
ELEDON PHARMACEUTICALS INC
$4.14M
1.64M sh0.77%-3.4% - HTFL
HEARTFLOW INC
$3.73M
74,969 sh0.69%-87.1% - BBOT
BRIDGEBIO ONCOLOGY THERAPEUT
$2.87M
699,532 sh0.53%+119.7% - KRSA
KORSANA BIOSCIENCES INC
$2.81M
87,702 sh0.52%New - FRNM
FREENOME INC
$2.49M
158,170 sh0.46%New - TARA
PROTARA THERAPEUTICS INC
$1.56M
512,287 sh0.29%-1.5% - KPTI
KARYOPHARM THERAPEUTICS INC
$1.19M
976,191 sh0.22%+3.8% - HYPR
HYPERFINE INC
$1.05M
1.30M sh0.20%-1.3% - MGX
METAGENOMI THERAPEUTICS INC
$561K
528,993 sh0.10%+0.0% - FTH
FAETH THERAPEUTICS INC
$438K
14,718 sh0.08%+0.0% - OM
OUTSET MED INC
$322K
107,456 sh0.06%-9.2% - ADRX
ADARX PHARMACEUTICALS INC
$226K
11,357 sh0.04%New
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
AVLN AVALYN PHARMACEUTICALS INC | 1.70M | $48.4M | +1.4% | 8.99% | Q3 2026 |
BMY BRISTOL-MYERS SQUIBB CO | 499,716 | $31.18M | +21.0% | 5.79% | Q3 2026 |
BBIO BRIDGEBIO PHARMA INC | 425,111 | $27.97M | -6.6% | 5.20% | Q3 2026 |
PBLS PARABILIS MEDICINES INC | 824,043 | $26.61M | +0.0% | 4.94% | Q3 2026 |
JNJ JOHNSON & JOHNSON | 99,496 | $26.34M | -28.4% | 4.89% | Q3 2026 |
ASND ASCENDIS PHARMA A/S | 101,445 | $23.11M | +219.4% | 4.29% | Q3 2026 |
ARWR ARROWHEAD PHARMACEUTICALS IN | 315,247 | $20.63M | New | 3.83% | Q3 2026 |
SNDX SYNDAX PHARMACEUTICALS INC | 1.02M | $19.24M | -15.8% | 3.57% | Q3 2026 |
DFTX DEFINIUM THERAPEUTICS INC | 497,964 | $18.95M | -11.5% | 3.52% | Q3 2026 |
CELC CELCUITY INC | 230,609 | $18.34M | New | 3.41% | Q3 2026 |
SEPN SEPTERNA INC | 454,015 | $17.77M | -15.3% | 3.30% | Q3 2026 |
GH GUARDANT HEALTH INC | 92,579 | $16.51M | New | 3.07% | Q3 2026 |
PTGX PROTAGONIST THERAPEUTICS INC | 112,418 | $15.84M | +5.3% | 2.94% | Q3 2026 |
TXG 10X GENOMICS INC | 164,029 | $14.82M | New | 2.75% | Q3 2026 |
AMLX AMYLYX PHARMACEUTICALS INC | 505,882 | $14.72M | New | 2.73% | Q3 2026 |
MLYS MINERALYS THERAPEUTICS INC | 583,364 | $14.66M | -10.1% | 2.72% | Q3 2026 |
EW EDWARDS LIFESCIENCES CORP | 161,121 | $13.91M | +29.1% | 2.58% | Q3 2026 |
CRVS CORVUS PHARMACEUTICALS INC | 1.02M | $11.77M | -5.5% | 2.19% | Q3 2026 |
MANE VERADERMICS INC | 95,646 | $11.6M | +108.6% | 2.15% | Q3 2026 |
ENTX ENTERA BIO LTD | 3.92M | $11.41M | New | 2.12% | Q3 2026 |
IRON DISC MEDICINE INC | 172,709 | $11.31M | +8.4% | 2.10% | Q3 2026 |
ODTX ODYSSEY THERAPEUTICS INC | 457,839 | $10.17M | +0.0% | 1.89% | Q3 2026 |
FDMT 4D MOLECULAR THERAPEUTICS IN | 684,753 | $9.8M | +45.3% | 1.82% | Q3 2026 |
RARE ULTRAGENYX PHARMACEUTICAL IN | 601,760 | $9.04M | +90.3% | 1.68% | Q3 2026 |
BMRN BIOMARIN PHARMACEUTICAL INC | 144,971 | $8.7M | New | 1.62% | Q3 2026 |
ANNX ANNEXON INC | 1.99M | $8.4M | New | 1.56% | Q3 2026 |
RYTM RHYTHM PHARMACEUTICALS INC | 85,614 | $8.15M | New | 1.51% | Q3 2026 |
GPCR STRUCTURE THERAPEUTICS INC | 260,109 | $8.13M | -6.0% | 1.51% | Q3 2026 |
NKTR NEKTAR THERAPEUTICS | 126,817 | $7.68M | New | 1.43% | Q3 2026 |
IMCR IMMUNOCORE HLDGS PLC | 211,985 | $6.42M | +43.2% | 1.19% | Q3 2026 |
COGT COGENT BIOSCIENCES INC | 167,716 | $5.37M | New | 1.00% | Q3 2026 |
KLRA KAILERA THERAPEUTICS INC | 468,750 | $5.35M | +0.0% | 0.99% | Q3 2026 |
NTRA NATERA INC | 12,530 | $5.18M | -84.8% | 0.96% | Q3 2026 |
GUTS FRACTYL HEALTH INC | 8.84M | $4.81M | +43.3% | 0.89% | Q3 2026 |
KARD KARDIGAN INC | 312,500 | $4.61M | +0.0% | 0.86% | Q3 2026 |
ELDN ELEDON PHARMACEUTICALS INC | 1.64M | $4.14M | -3.4% | 0.77% | Q3 2026 |
HTFL HEARTFLOW INC | 74,969 | $3.73M | -87.1% | 0.69% | Q3 2026 |
BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 699,532 | $2.87M | +119.7% | 0.53% | Q3 2026 |
KRSA KORSANA BIOSCIENCES INC | 87,702 | $2.81M | New | 0.52% | Q3 2026 |
FRNM FREENOME INC | 158,170 | $2.49M | New | 0.46% | Q3 2026 |
TARA PROTARA THERAPEUTICS INC | 512,287 | $1.56M | -1.5% | 0.29% | Q3 2026 |
KPTI KARYOPHARM THERAPEUTICS INC | 976,191 | $1.19M | +3.8% | 0.22% | Q3 2026 |
HYPR HYPERFINE INC | 1.30M | $1.05M | -1.3% | 0.20% | Q3 2026 |
MGX METAGENOMI THERAPEUTICS INC | 528,993 | $561K | +0.0% | 0.10% | Q3 2026 |
FTH FAETH THERAPEUTICS INC | 14,718 | $438K | +0.0% | 0.08% | Q3 2026 |
OM OUTSET MED INC | 107,456 | $322K | -9.2% | 0.06% | Q3 2026 |
ADRX ADARX PHARMACEUTICALS INC | 11,357 | $226K | New | 0.04% | Q3 2026 |
1-47 of 47 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
Catalio Capital Management, LP filed its most recent 13F holdings report, covering Q3 2026 (the quarter ended Sep 30, 2026), on Nov 16, 2026. Its largest reported positions by value are AVLN, BMY, BBIO, PBLS and JNJ. A 13F lists US-listed stock and option positions, not total assets under management.
About Catalio Capital Management, LP
Catalio Capital Management, LP is a Mutual Fund that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1958125). Signal8 holds 21 13F filings from it. Its SEC filings list New York as its state of incorporation.
Its most recent 13F holdings report covers Q3 2026 (the quarter ended Sep 30, 2026) and was filed on Nov 16, 2026. That report lists 47 securities, not counting options, up from 39 in Q2 2026.
Its five largest reported positions, in order, are AVALYN PHARMACEUTICALS INC (AVLN), BRISTOL-MYERS SQUIBB CO (BMY), BRIDGEBIO PHARMA INC (BBIO), PARABILIS MEDICINES INC (PBLS) and JOHNSON & JOHNSON (JNJ). The next five are ASCENDIS PHARMA A/S (ASND), ARROWHEAD PHARMACEUTICALS IN (ARWR), SYNDAX PHARMACEUTICALS INC (SNDX), DEFINIUM THERAPEUTICS INC (DFTX) and CELCUITY INC (CELC).
Recent 13F filings by Catalio Capital Management, LP
- Q3 2026: 13F-HR filed Nov 16, 2026, listing 47 securities.
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 39 securities.
- Q1 2026: 13F-HR filed May 15, 2026, listing 41 securities.
- Q4 2025: 13F-HR/A filed Sep 2, 2026, listing 45 securities.
- Q4 2025: 13F-HR filed Feb 17, 2026, listing 45 securities.
- Q3 2025: 13F-HR filed Nov 14, 2025, listing 38 securities.